FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure - Scorecard - MDSpire

FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

Phase 3 data showed a 67% reduction in symptomatic infection among exposed household contacts who tested negative at baseline.

  • By

  • Kathryn Wighton

  • June 2, 2026

  • 3 min

Share

Clinical Scorecard: FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

At a Glance

CategoryDetail
Condition
Key MechanismsSARS-CoV-2 main protease inhibitor that suppresses viral replication
Target Population
Care Setting

Key Highlights

  • First and only oral option for COVID-19 postexposure prophylaxis
  • 67% reduction in symptomatic COVID-19 risk through day 10 compared to placebo

Guideline-Based Recommendations

Diagnosis

  • Participants must test negative for SARS-CoV-2 at enrollment

Management

  • Administer ensitrelvir as a 5-day regimen: three tablets on day 1, one tablet daily on days 2-5

Monitoring & Follow-up

  • Monitor for adverse events, particularly headache, diarrhea, and cough

Risks

  • No cases of dysgeusia attributed to ensitrelvir reported in the trial

Patient & Prescribing Data

Individuals aged 12 years and older exposed to symptomatic COVID-19

Effective in reducing symptomatic COVID-19 risk when administered postexposure

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

    • by Kathryn Wighton

    • June 2, 2026

    Related Content

    Raman Spectroscopy Moves to the Front Line of Pandemic Preparedness

    Comprehensive review highlights label-free viral detection – and the hurdles to real-world deployment

    • May 7, 2026

    • 2 min
    FDA Monthly Preview: Key June Decisions to Watch

    Several FDA decisions across multiple specialties are expected this month.

    Top 10 States With Rising Demand for Physicians

    These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.